Vesa LLM - Faron Pharmaceuticals General Counsel
| FARN Stock | 176.50 1.50 0.86% |
Executive
Vesa LLM is General Counsel of Faron Pharmaceuticals Oy
| Age | 53 |
| Address | Joukahaisenkatu 6 B, Turku, Finland, 20520 |
| Phone | 358 2469 5151 |
| Web | https://www.faron.com |
Faron Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (1.0264) % which means that it has lost $1.0264 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (39.615) %, meaning that it generated substantial loss on money invested by shareholders. Faron Pharmaceuticals' management efficiency ratios could be used to measure how well Faron Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Total Assets is likely to drop to about 10.8 M in 2025. Non Current Assets Total is likely to drop to about 1.3 M in 2025Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Neil Curtis | Seche Environnement SA | N/A | |
| Steve Bugajski | United States Steel | N/A | |
| Sascha Guenther | Oakley Capital Investments | N/A | |
| Guillaume Seche | Seche Environnement SA | 42 | |
| Tara Carraro | United States Steel | N/A | |
| Sylvain Durecu | Seche Environnement SA | N/A | |
| Samuel CFA | BlackRock Frontiers Investment | N/A | |
| John Gordon | United States Steel | N/A | |
| Adam Ryan | Aberdeen Diversified Income | N/A | |
| Rosanna Heward | Oakley Capital Investments | N/A | |
| Manuel Andersen | Seche Environnement SA | N/A | |
| Laurent Carmona | Seche Environnement SA | N/A | |
| Jonathan Clapham | Oakley Capital Investments | N/A | |
| Baptiste Janiaud | Seche Environnement SA | N/A | |
| Bertrand Filet | Seche Environnement SA | N/A | |
| Emily CFA | United States Steel | N/A | |
| Meghan Cox | United States Steel | N/A | |
| Richard CFA | Chrysalis Investments | N/A | |
| Mike Brooks | Aberdeen Diversified Income | N/A | |
| CFA CFA | BlackRock Frontiers Investment | N/A | |
| Scott Buckiso | United States Steel | 58 | |
Management Performance
| Return On Equity | -39.61 | ||||
| Return On Asset | -1.03 |
Faron Pharmaceuticals Leadership Team
Elected by the shareholders, the Faron Pharmaceuticals' board of directors comprises two types of representatives: Faron Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Faron. The board's role is to monitor Faron Pharmaceuticals' management team and ensure that shareholders' interests are well served. Faron Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Faron Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Juhana Heinonen, Chief Officer | ||
| Birge MD, Interim Officer | ||
| Markku Jalkanen, Founder Director | ||
| Vesa LLM, General Counsel | ||
| MD MSc, Chief Officer | ||
| Jennifer SmithParker, Head Communications | ||
| Maija Hollmen, Chief Officer | ||
| Petri MD, Chief Officer | ||
| MSc MSc, Interim Officer |
Faron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Faron Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -39.61 | ||||
| Return On Asset | -1.03 | ||||
| Current Valuation | 197.46 M | ||||
| Shares Outstanding | 111.6 M | ||||
| Shares Owned By Insiders | 30.61 % | ||||
| Shares Owned By Institutions | 7.26 % | ||||
| Price To Book | 165.73 X | ||||
| Price To Sales | 16.21 X | ||||
| Gross Profit | 803 K | ||||
| EBITDA | (18.36 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Faron Stock Analysis
When running Faron Pharmaceuticals' price analysis, check to measure Faron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Faron Pharmaceuticals is operating at the current time. Most of Faron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Faron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Faron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Faron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.